When does semaglutide patent expire in uk?

In the UK, semaglutide’s “patent expiry” isn’t a single date—there are multiple patents and extensions (for different inventions and formulations), and the final availability outcome depends on which IP rights remain in force for a given product.

That said, here’s the practical picture for semaglutide in the UK:

• Ozempic® (semaglutide, injectable for diabetes): the key UK patent(s) covering the medicine substance/lead protection are generally understood to run into the mid‑to‑late 2020s, with a common reference being around 2030 for full expiry of the core protection.
• Wegovy® (semaglutide for weight management): because it relies on the same active ingredient but often with additional/related patent layers for use and formulation, the relevant protection typically extends to roughly a similar timeframe, again often cited around 2030 depending on the specific patent families and their granted/extended status in the UK.

Important caveats

• Exact dates can differ based on which specific UK patent number, whether SPCs (Supplementary Protection Certificates) were granted, and each country’s national phase.
• Also, “patent expiry” ≠ “generic launch date.” Generics/biosimilars can sometimes enter earlier/later depending on regulatory exclusivities, litigation, and remaining rights.

If you want the precise date(s)

Tell me which product you mean:

1. Ozempic (diabetes) or Wegovy (weight loss), and
2. If you know it, the manufacturer (Novo Nordisk product) or any specific UK patent number you’re looking at.

And I can help you pin down the exact UK patent/SPC expiry timing for that product.